Articles

RELIABILITY OF FUNCTIONAL COMPRESSIVE BANDAGING IN THE TREATMENT OF LYMPHEDEMA SECONDARY TO THE TREATMENT OF BREAST CANCER

Authors
  • A. Apolinário (University of São Paulo)
  • É.L. Kohl Lima (University of São Paulo)
  • G.C. Borsari (University of São Paulo)
  • M.S. Rezende (University of São Paulo)
  • F.B. Rangon (University of São Paulo)
  • D.M. Rossi (University of São Paulo)
  • E.C. de Oliveira Guirro (University of São Paulo)

Abstract

Functional compressive bandaging (FCB) is a therapeutic resource used to control lymphedema resulting from the treatment of breast cancer. However, the reliability of the technique is unknown. We evaluated intra- and inter-rater reliability of the spiral technique in the four-layer FCB of the arm and forearm in breast cancer survivors with lymphedema. Forty-five breast cancer survivors with a mean age of 64.88±10.01 years participated in the study. Evaluations were performed by two examiners at different times analyzing the pressure exerted (mmHg) by the spiral FCB in the arm and forearm of the upper limb affected by lymphedema. The intraclass correlation coefficient (ICC2,1) was used to determine intra- and inter-examiner reliability, with a 95% confidence interval, minimum detectable change, and standard error of the measurement. Intra-rater reliability was considered low to high in the arm and forearm region. Inter-rater reliability in the arm region was considered low and in the forearm region low to moderate. Our results indicate that spiral FCB has low to moderate intra-examiner and inter-examiner reliability.

Keywords: lymphedema, breast cancer, compressive bandaging, rater reliability

How to Cite:

Apolinário, A. & Kohl Lima, É. & Borsari, G. & Rezende, M. & Rangon, F. & Rossi, D. & de Oliveira Guirro, E., (2022) “RELIABILITY OF FUNCTIONAL COMPRESSIVE BANDAGING IN THE TREATMENT OF LYMPHEDEMA SECONDARY TO THE TREATMENT OF BREAST CANCER”, Lymphology 55(2), 47-53. doi: https://doi.org/10.2458/lymph.5265

Downloads:
Download PDF

249 Views

726 Downloads

Published on
20 Sep 2022
Peer Reviewed